This model predicts that adjuvant atezolizumab following chemotherapy provides a considerable population-level reduction in recurrences among patients with PD-L1–high eNSCLC and reduces the treatment costs and economic burden of recurrent NSCLC in Canada. This evidence concerns the gene CD274 and non-small cell lung carcinoma.